阿达木单抗在儿童多关节型幼年特发性关节炎、附着点炎相关关节炎、银屑病及克罗恩病中的安全性
该分析汇总7项由AbbVie赞助的全球随机及开放标签临床试验及其开放标签延伸研究(2002年9月至2015年12月31日)中577例接受≥1剂阿达木单抗皮下注射的儿科患者,共1440.7患者年暴露。结果显示最常见不良事件为上呼吸道感染(24.3事件/100患者年)、头痛(19.9)和鼻咽炎(17.3),严重感染为最常见严重不良事件(4.0事件/100患者年),未报告恶性肿瘤事件,发生1例意外跌倒死亡。结论认为阿达木单抗在所列儿科适应症中安全性总体相似,未发现新的安全性信号。
要点
- 577例儿科患者共1440.7患者年阿达木单抗暴露,最常见不良事件为上呼吸道感染(24.3事件/100患者年)。
- 严重感染为最常见严重不良事件(4.0事件/100患者年),最常见为肺炎(0.6事件/100患者年)。
- 未报告恶性肿瘤事件,发生1例意外跌倒死亡;各适应症安全性总体相似,未发现新安全性信号。
核心结论
- 阿达木单抗在儿童多关节型幼年特发性关节炎、附着点炎相关关节炎、银屑病及克罗恩病中的安全性总体相似,未发现新的安全性信号。
研究设计与样本
- 本分析纳入7项由AbbVie赞助的全球随机及开放标签阿达木单抗临床试验及其开放标签延伸研究,研究期间为2002年9月至2015年12月31日。
- 纳入接受≥1剂阿达木单抗皮下注射的儿科患者,报告首次给药后至末次给药后70天(5个半衰期)内发生的不良事件,并计算每100患者年事件数。
主要发现
- 分析共纳入577例儿科患者,代表1440.7患者年的阿达木单抗暴露。
- 跨适应症最常见不良事件为上呼吸道感染(24.3事件/100患者年)、头痛(19.9事件/100患者年)和鼻咽炎(17.3事件/100患者年)。
- 严重感染为跨适应症最常见严重不良事件(4.0事件/100患者年),最常见为肺炎(0.6事件/100患者年)。
- 严重感染率在幼年特发性关节炎、银屑病和克罗恩病患者中分别为2.7、0.8和6.6事件/100患者年。
- 未报告恶性肿瘤事件;银屑病患者中发生1例意外跌倒死亡。
临床怎么用
- 在儿科上述适应症中使用阿达木单抗时,可参考本分析中各适应症的严重感染发生率(幼年特发性关节炎2.7、银屑病0.8、克罗恩病6.6事件/100患者年)进行安全性监测。
- 治疗期间应关注上呼吸道感染、鼻咽炎、头痛及严重感染(尤其肺炎)等常见不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety of adalimumab in pediatric patients who participated in clinical trials of juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and pediatric enthesitis-related arthritis), psoriasis, and Crohn's disease. STUDY DESIGN: This analysis included data from 7 global, randomized, and open-label AbbVie-sponsored clinical trials of adalimumab and their open-label extensions conducted between September 2002 and December 31, 2015 (cutoff date for ongoing studies). Patients who received ≥1 dose of adalimumab subcutaneously were included. Adverse events that occurred after the first dose of adalimumab and up to 70 days (5 half-lives) after the last dose were reported and events per 100 patient-years were calculated. RESULTS: The analysis included 577 pediatric patients, representing 1440.7 patient-years of adalimumab exposure. Across indications, the most commonly reported adverse events (events/100 patient-years) were upper respiratory tract infections (24.3), nasopharyngitis (17.3), and headache (19.9). Serious infections (4.0 events/100 patient-years) were the most frequent serious adverse events across indications; the most commonly reported was pneumonia (0.6 events/100 patient-years). Serious infection rates were 2.7, 0.8, and 6.6 events/100 patient-years in patients with juvenile idiopathic arthritis, psoriasis, and Crohn's disease, respectively. No events of malignancies were reported. One death (accidental fall) occurred in a patient with psoriasis. CONCLUSIONS: The safety profile of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn's disease was generally similar across indications; no new safety signals were identified in the treatment of pediatric patients with adalimumab. TRIAL REGISTRATION: Clinicaltrials.gov: NCT00048542, NCT00775437, NCT00690573, NCT01166282, NCT01251614, NCT00409682, and NCT00686374.
引用
- Horneff G, Seyger MMB, Arikan D, et al. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. J Pediatr. 2018. PMID: 30054164. doi:10.1016/j.jpeds.2018.05.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。